PX 478

Drug Profile

PX 478

Alternative Names: PX-478

Latest Information Update: 21 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProlX Pharmaceuticals
  • Developer Oncothyreon
  • Class Antineoplastics; Mustard compounds; Phenylpropionates; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Jun 2010 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a Phase-I trial in Cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010) ,
  • 14 May 2010 Oncothyreon completes a phase I trial in Solid tumours and lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top